Allarity Therapeutics, Inc. (ALLR) Research

Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new cancer treatments. They utilize a unique "drug response predictor" technology to generate specific companion diagnostics, aiming to identify which patients will best respond to their various oncology therapeutics. The company's portfolio of investigational drugs for various cancers includes: Stenoparib: A poly-ADP-ribose polymerase (PARP) inhibitor currently in Phase 2 clinical trials for ovarian cancer. Dovitinib: A pan-tyrosine kinase inhibitor designed to treat renal cell carcinoma. IXEMPRA: A microtubule inhibitor used in the treatment of metastatic breast cancer. LiPlaCis: A liposomal formulation of cisplatin, undergoing Phase 2 clinical trials for metastatic breast cancer. 2X-111: A liposomal formulation of doxorubicin, also in Phase 2 studies for both metastatic breast cancer and glioblastoma multiforme. Established in 2004, Allarity Therapeutics maintains its headquarters in Cambridge, Massachusetts.

Market snapshot

Symbol
ALLR
Price
$1.43
Day change
+6.72%
Market cap
$22.8M
P/E ratio
-2.03x
52-week range
0.769-2.35
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months

Peer companies

  • BriaCell Therapeutics Corp. (BCTX)
  • CASI Pharmaceuticals, Inc. (CASI)
  • Cingulate Inc. (CING)
  • Clearside Biomedical, Inc. (CLSD)
  • Curis, Inc. (CRIS)
  • Entero Therapeutics, Inc. (ENTO)
  • Kairos Pharma, Ltd. (KAPA)
  • Lexaria Bioscience Corp. (LEXX)

Recent insider activity

  • Jensen Thomas — A-Award (200000 shares) on 2026-01-28
  • Hoeiland Jesper — A-Award (25000 shares) on 2026-01-07
  • Hoeiland Jesper — trade (0 shares) on 2025-06-10
  • McLaughlin Gerald W. — A-Award (45000 shares) on 2026-01-28
  • Graff Jeremy R. — A-Award (133333 shares) on 2026-01-28

Open Allarity Therapeutics, Inc. (ALLR) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.